Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma

Sixty-four transplant-eligible patients with newly diagnosed multiple myeloma (NDMM) received carfilzomib (days 1, 2, 8, 9, 15, 16), 300 mg/m(2) cyclophosphamide (days 1, 8, 15), 100 mg thalidomide (days 1–28) and 40 mg dexamethasone (days 1, 8, 15, 22) in 28-day cycles (CYKLONE regimen). Carfilzomi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Haematol
Autors principals: Mikhael, Joseph R., Reeder, Craig B., Libby, Edward N., Costa, Luciano J., Bergsagel, P. Leif, Buadi, Francis, Mayo, Angela, Nagi Reddy, Sravan K., Gano, Katherine, Dueck, Amylou C., Stewart, A. Keith
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4521972/
https://ncbi.nlm.nih.gov/pubmed/25683772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13296
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars